eligibility_summary
Eligible: patients with advanced protocol-specified solid tumors, confirmed ROR1 expression, and progression after ≥1 systemic therapy, with no further standard options or intolerance/contraindication. Exclude: prior ROR1-targeted or CD3 T-cell-engaging therapy, CAR cell therapy within 90 days, systemic therapy within 5 half-lives or 21 days, wide-field RT within 28 days, focal RT within 14 days, or unresolved toxicities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: NM32-2668, an anti-ROR1/CD3/HSA tri-specific antibody (biologic T‑cell engager). Mechanism: simultaneously binds ROR1 on tumor cells and CD3 on T cells to create an immunologic synapse, activating cytotoxic T‑cell killing of ROR1+ cancers, the anti‑HSA arm binds human serum albumin to extend half‑life and exposure. Targets/cells/pathways: ROR1 (receptor tyrosine kinase-like orphan receptor 1) on selected solid tumors, CD3 on T lymphocytes (TCR complex) to drive T‑cell activation, proliferation, cytokine release, and tumor cell lysis, albumin/FcRn recycling pathway for pharmacokinetic enhancement. Population: adults with ROR1‑expressing advanced solid tumors. Status: Phase 1, first‑in‑human, terminated for business reasons.